Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.

BG Medicine wants to fill big gaps in diagnostic medicine. The biosciences researcher primarily provides drug research and development services to such top global pharmaceutical makers as Pfizer and AstraZeneca, US government agencies, and to the health care product divisions of companies like Mitsubishi. BG Medicine specializes in developing biomarkers, substances used to detect disease at a molecular level, that enable research into the causes of disease and the effectiveness of drugs used to treat them. Products in the planning and discovery stages include molecular diagnostic tests for heart disease, neurological disorders, and cancer.

Mirus Bio provides gene transfer technologies to the pharmaceutical industry. The company's reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. Besides its kits, Mirus Bio is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Mirus Bio has agreed to be acquired by Roche Holding for $125 million.

Compugen Ltd. company was founded in 1993 and is based in Tel Aviv, Israel. Compugen Ltd. (Compugen) is engaged in drug and diagnostic product candidate discovery and the commercialization of such candidates through early-stage licensing and co-development agreements. The Company’s business is focused on developing and using predictive computer-based discovery platforms to discover therapeutic drug candidates and diagnostic biomarker candidates. The Company uses experimental biological processes to validate product candidates discovered by its predictive platforms. Its initial discovery platforms focused mainly on cancer, cardiovascular and immune-related diseases. In July 2008, Compugen announced results from an in vivo study of CGEN-25007, a peptide antagonist of the gp96 protein. The data indicate that CGEN-25007 has immunosuppressive effects and therapeutic potential for the treatment of various inflammatory diseases and other immune related pathologies.

CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

Senesco Technologies Inc. company was founded in 1964 and is headquartered in New Brunswick, New Jersey. Senesco Technologies, Inc. (Senesco) is a development-stage biotechnology company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing its eucaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for inhibition in human health applications to develop approaches to treat inflammatory diseases and cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants.

SkinMedica, Inc. was founded in 1999 and is headquartered in Carlsbad, California. SkinMedica, Inc. operates as a specialty pharmaceutical company that focuses on developing, acquiring, and commercializing products that treat dermatologic conditions and diseases and enhances the appearance of skin. It offers gels for the treatment of mild to moderate atopic dermatitis; creams for the reduction in growth of unwanted facial hair in women; franchises for the treatment of acne; and products for the treatment of hyperpigmentation. The company also provides anti aging products, aesthetic skin care, moisturizers, and sun protection, eye products, as well as facial and sensitive skin cleansers, rejuvenative and acne treatment toners, and skin polishers. It markets and sells prescription pharmaceutical products, and physician-dispensed and non-prescription skin care products primarily to dermatologists and pediatricians.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.